Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct;149(13):11025-11030.
doi: 10.1007/s00432-023-04995-6. Epub 2023 Jun 19.

SARS-CoV-2 Omicron BA.5.2-infection and COVID-19 in persons with chronic myeloid leukaemia

Fang Cheng #  1   2 , Hang Xiang #  3 , Robert Peter Gale  4 , Siyi Chen  5 , Jiao Qu  6 , Hao Guo  7 , Qiubai Li  8   9 , Yanli Zhang  10 , Weiming Li  11
Affiliations

SARS-CoV-2 Omicron BA.5.2-infection and COVID-19 in persons with chronic myeloid leukaemia

Fang Cheng et al. J Cancer Res Clin Oncol. 2023 Oct.

Abstract

Objective: A SARS-CoV-2 Omicron (BA.5.2) epidemic began in China in December, 2022 following stopping the zero COVID policy.

Methods: We studied features of the epidemic in 1,121 persons with chronic myeloid leukaemia (CML).

Results: 1103 (98%) were in chronic, 10 in accelerated and 8 in acute phases. 834 (74%) became infected almost all of whom met criteria for COVID-19. The most common symptoms were fever (91%), cough (90%) and fatigue (82%). 42 infected persons were asymptomatic. Most people quarantined at home and self-medicated. 22 were hospitalized for COVID-19. At admission 5 had mild, 14, moderate and 3, severe/critical disease according to World Health Organization (WHO) criteria. 5 received respiratory assistance, 3 were admitted to the intensive care unit (ICU) and 1 in accelerated phase died from COVID-19. Co-variates associated with a risk of COVID-19 in SARS-CoV-2-infected subjects include age ≥ 65 years, higher education level and imatinib therapy.

Conclusion: In conclusion, most SARS-CoV-2 Omicron BA.5.2 infections in persons with CML resulted in COVID-19 most of which cases are mild with only 1 death.

Keywords: COVID-19; Chronic myeloid leukaemia; Omicron BA.5.2; SARS-CoV-2 Omicron.

PubMed Disclaimer

Conflict of interest statement

RPG is a consultant to Antengene Biotech LLC, Ascentage Pharma Group and NexImmune Inc.; Medical Director, FFF Enterprises Inc.; Board of Directors: Russian Foundation for Cancer Research Support; and Scientific Advisory Boards, Nanexa AB and StemRad Ltd.

Figures

Fig. 1
Fig. 1
CONSORT flow diagram
See this image and copyright information in PMC

References

    1. Banerjee S, Yadav S, Banerjee S, Fakayode SO, Parvathareddy J, Reichard W et al (2021) Drug repurposing to identify nilotinib as a potential SARS-CoV-2 main protease inhibitor: insights from a computational and in vitro study. J Chem Inf Model 61(11):5469–5483. 10.1021/acs.jcim.1c00524 - PMC - PubMed
    1. Başcı S, Ata N, Altuntaş F, Yiğenoğlu TN, Dal MS, Korkmaz S et al (2020) Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors. J Oncol Pharm Pract 26(7):1676–1682. 10.1177/1078155220953198 - PMC - PubMed
    1. Breccia M, Abruzzese E, Accurso V, Attolico I, Barulli S, Bergamaschi M et al (2022) COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. Br J Haematol 196(3):559–565. 10.1111/bjh.17890 - PMC - PubMed
    1. Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J et al (2014) Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother 58(8):4885–4893. 10.1128/aac.03036-14 - PMC - PubMed
    1. Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F et al (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34(4):966–984. 10.1038/s41375-020-0776-2 - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources